These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28697053)

  • 1. Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy.
    Matsui H; Hazama S; Sakamoto K; Shindo Y; Kanekiyo S; Nakashima M; Matsukuma S; Tokuhisa Y; Iida M; Suzuki N; Yoshimura K; Takeda S; Ueno T; Yoshino S; Oka M; Nagano H
    Pancreas; 2017 Sep; 46(8):994-1002. PubMed ID: 28697053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer.
    Shindo Y; Hazama S; Maeda Y; Matsui H; Iida M; Suzuki N; Yoshimura K; Ueno T; Yoshino S; Sakai K; Suehiro Y; Yamasaki T; Hinoda Y; Oka M
    J Transl Med; 2014 Jun; 12():175. PubMed ID: 24947606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.
    Kawaoka T; Oka M; Takashima M; Ueno T; Yamamoto K; Yahara N; Yoshino S; Hazama S
    Oncol Rep; 2008 Jul; 20(1):155-63. PubMed ID: 18575732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A case of metastatic pancreatic cancer with a remarkable response to combination therapy of gemcitabine and adoptive immune cell therapy].
    Imai N; Takeda K; Utsunomiya S; Taga M; Kawata N; Ikeda T; Mizutani Y; Hirose K; Ishikawa T; Yoshida S
    Gan To Kagaku Ryoho; 2010 Mar; 37(3):527-9. PubMed ID: 20332697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer.
    Hirooka Y; Itoh A; Kawashima H; Hara K; Nonogaki K; Kasugai T; Ohno E; Ishikawa T; Matsubara H; Ishigami M; Katano Y; Ohmiya N; Niwa Y; Yamamoto K; Kaneko T; Nieda M; Yokokawa K; Goto H
    Pancreas; 2009 Apr; 38(3):e69-74. PubMed ID: 19276867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.
    Dalgleish AG; Stebbing J; Adamson DJ; Arif SS; Bidoli P; Chang D; Cheeseman S; Diaz-Beveridge R; Fernandez-Martos C; Glynne-Jones R; Granetto C; Massuti B; McAdam K; McDermott R; Martín AJ; Papamichael D; Pazo-Cid R; Vieitez JM; Zaniboni A; Carroll KJ; Wagle S; Gaya A; Mudan SS
    Br J Cancer; 2016 Sep; 115(7):789-96. PubMed ID: 27599039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.
    Ohigashi H; Ishikawa O; Eguchi H; Takahashi H; Gotoh K; Yamada T; Yano M; Nakaizumi A; Uehara H; Tomita Y; Nishiyama K
    Ann Surg; 2009 Jul; 250(1):88-95. PubMed ID: 19561477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients.
    Miyazawa M; Katsuda M; Maguchi H; Katanuma A; Ishii H; Ozaka M; Yamao K; Imaoka H; Kawai M; Hirono S; Okada KI; Yamaue H
    Int J Cancer; 2017 Feb; 140(4):973-982. PubMed ID: 27861852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant combination therapy with gemcitabine and autologous γδ T-cell transfer in patients with curatively resected pancreatic cancer.
    Aoki T; Matsushita H; Hoshikawa M; Hasegawa K; Kokudo N; Kakimi K
    Cytotherapy; 2017 Apr; 19(4):473-485. PubMed ID: 28188072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphatic invasion is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with gemcitabine or S-1.
    Aoyama T; Murakawa M; Katayama Y; Shiozawa M; Ueno M; Morimoto M; Yoshikawa T; Rino Y; Masuda M; Morinaga S
    Hepatogastroenterology; 2015; 62(138):472-7. PubMed ID: 25916085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes.
    Kondo H; Hazama S; Kawaoka T; Yoshino S; Yoshida S; Tokuno K; Takashima M; Ueno T; Hinoda Y; Oka M
    Anticancer Res; 2008; 28(1B):379-87. PubMed ID: 18383873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life.
    Toyama Y; Yoshida S; Saito R; Kitamura H; Okui N; Miyake R; Ito R; Son K; Usuba T; Nojiri T; Yanaga K
    World J Surg Oncol; 2013 Jan; 11():3. PubMed ID: 23302293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials.
    Kurreck A; Weckwerth J; Modest DP; Striefler JK; Bahra M; Bischoff S; Pelzer U; Oettle H; Kruger S; Riess H; Sinn M
    Eur J Cancer; 2021 Jun; 150():250-259. PubMed ID: 33940349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A study of recurrent pancreatic cancer with metastatic liver tumors after pancreatectomy].
    Horiuchi H; Uchida S; Hisaka T; Ishikawa H; Sakai T; Kawahara R; Kinoshita H; Shirouzu K
    Gan To Kagaku Ryoho; 2005 Oct; 32(11):1685-7. PubMed ID: 16315909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical resection deteriorates gemcitabine-induced leukopenia in pancreatic cancer.
    Onoue M; Terada T; Okuda M; Fujimoto K; Doi R; Imamura M; Inui K
    Int J Clin Oncol; 2004 Jun; 9(3):174-8. PubMed ID: 15221601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study.
    Van Laethem JL; Demols A; Gay F; Closon MT; Collette M; Polus M; Houbiers G; Gastelblum P; Gelin M; Houtte PV; Closset J
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):974-80. PubMed ID: 12829132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer.
    Mayanagi S; Kitago M; Sakurai T; Matsuda T; Fujita T; Higuchi H; Taguchi J; Takeuchi H; Itano O; Aiura K; Hamamoto Y; Takaishi H; Okamoto M; Sunamura M; Kawakami Y; Kitagawa Y
    Cancer Sci; 2015 Apr; 106(4):397-406. PubMed ID: 25614082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients.
    Yanagimoto H; Shiomi H; Satoi S; Mine T; Toyokawa H; Yamamoto T; Tani T; Yamada A; Kwon AH; Komatsu N; Itoh K; Noguchi M
    Oncol Rep; 2010 Sep; 24(3):795-801. PubMed ID: 20664989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer.
    Nio Y; Hashimoto K; Yano S; Itakura M; Koike M; Yamaguchi K; Endo S; Tsuji M; Higami T; Maruyama R
    Oncol Rep; 2005 Aug; 14(2):401-8. PubMed ID: 16012722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expression.
    Kobayashi M; Mizuno S; Murata Y; Kishiwada M; Usui M; Sakurai H; Tabata M; Ii N; Yamakado K; Inoue H; Shiraishi T; Yamada T; Isaji S
    Pancreas; 2014 Apr; 43(3):350-60. PubMed ID: 24622063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.